You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company announces results from its extension study of its Phase 2 study investigating the safety and immune responses of its universal RSV vaccine, MVA-BN RSV, in an older adult population. In 2017, the company reported data from a Phase 2 study that investigated various schedules and doses oAlready a…
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal cancer and liver cancer. The Phase III ADAURA trial showed for example that treatment with Tagrisso after surgery with curative intent reduced the risk oAlready a subscriber Login You have…
The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season. The trial assessed the safety of nirsevimab in infants with chronic lung disAlready a subscriber Login You…
Immunicum has announced an update on survival data from the randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with SutentÒ (sunitinib) first-line treatment regimen in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). DuriAlready a subscriber Login You have read all your free articles,…
